Bailard Inc. increased its stake in Regeneron Pharmaceuticals by 10.1% in Q4, raising its holdings to 13,422 shares.

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 </stron ...

Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...

PC hardware is nice, but it’s not much use without innovative software. I’ve been reviewing software for PCMag since 2008, and I still get a kick out of seeing what's new in video and photo ...

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors.

SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... for our investment conferences and advertising on our websites and newsletters. How we use your information depends ...

Eye­Point Phar­ma­ceu­ti­cals, a biotech at­tempt­ing to grab a sliv­er of Re­gen­eron’s share of the de­gen­er­a­tive eye dis­ease mar­ket, said six-month re­sults show its ...